Can a diabetes drug shield hearts from chemo damage?
NCT ID NCT06888505
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether dapagliflozin (Farxiga), a drug used for diabetes and heart failure, can prevent heart damage caused by anthracycline chemotherapy. 94 adults with cancer took either dapagliflozin or a placebo daily for four months alongside their chemo. Researchers measured heart function and blood markers to see if the drug offered protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (Farxiga)
What this could lead to
If it works, this could point toward a way to protect the heart during chemotherapy, reducing the risk of long-term heart damage.
What could go wrong
This is a small, early-phase trial with only 94 participants. The results may not apply to everyone, and the drug may not provide meaningful protection in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azadi Oncology Centre
Duhok, Duhok Governorate, 42001, Iraq